Literature DB >> 9763578

Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-gamma and interferon- in interleukin-6 (IL-6)-dependent and IL-6-independent multiple myeloma cell lines.

H Spets1, P Georgii-Hemming, J Siljason, K Nilsson, H Jernberg-Wiklund.   

Abstract

A poor response to Fas-induced apoptosis is evident in some multiple myeloma (MM) cell lines and primary cells. In this study, we have examined the possibility to increase the sensitivity to Fas-induced apoptosis by pretreatment of MM cells with interferon-gamma (IFN-gamma) or interferon-alpha (IFN-alpha). Both IFN-gamma and IFN-alpha markedly increased the Fas-induced apoptosis in all cell lines tested (U-266-1970, U-266-1984, and U-1958). In the U-266-1970 and U-1958 cell lines, pretreatment with either IFN-gamma or IFN-alpha also inhibited proliferation in a dose-dependent manner. In contrast, IFN-gamma activation of the Fas death pathway in the U-266-1984 cells was not accompanied by growth inhibition. Incubation with the IFNs increased the Fas antigen expression in one of three cell lines but did not alter the expression of Bcl-2 or Bax. The IFNs are important regulators of growth and survival in MM cells. Our results suggest that activation of Fas-mediated apoptosis is a novel mechanism by which the IFNs exert inhibitory effects on MM cells. Copyright 1998 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9763578

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Glatiramer acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from multiple sclerosis patients.

Authors:  M Ruggieri; C Avolio; S Scacco; C Pica; A Lia; G B Zimatore; S Papa; P Livrea; M Trojano
Journal:  J Neurol       Date:  2005-09-30       Impact factor: 4.849

Review 2.  Regulation of autoreactive anti-IgG (rheumatoid factor) B cells in normal and autoimmune mice.

Authors:  H Wang; M J Schlomchik
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

3.  The mitochondrial pathway and reactive oxygen species are critical contributors to interferon-α/β-mediated apoptosis in Ubp43-deficient hematopoietic cells.

Authors:  Hwa Young Yim; Young Yang; Jong-Seok Lim; Myeong Seok Lee; Dong-Er Zhang; Keun Il Kim
Journal:  Biochem Biophys Res Commun       Date:  2012-06-05       Impact factor: 3.575

4.  Apo2L/TRAIL and Bcl-2-related proteins regulate type I interferon-induced apoptosis in multiple myeloma.

Authors:  Q Chen; B Gong; A S Mahmoud-Ahmed; A Zhou; E D Hsi; M Hussein; A Almasan
Journal:  Blood       Date:  2001-10-01       Impact factor: 22.113

5.  Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma.

Authors:  Asuka Nanbo; Kaori Inoue; Kumi Adachi-Takasawa; Kenzo Takada
Journal:  EMBO J       Date:  2002-03-01       Impact factor: 11.598

6.  Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection.

Authors:  E Stylianou; P Aukrust; K Bendtzen; F Müller; S S Frøland
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

Review 7.  Apoptosis and cell growth inhibition as antitumor effector functions of interferons.

Authors:  H Strander
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

8.  Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma.

Authors:  Amorette Barber; Tong Zhang; Christina J Megli; Jillian Wu; Kenneth R Meehan; Charles L Sentman
Journal:  Exp Hematol       Date:  2008-07-02       Impact factor: 3.084

9.  Antiproliferative Properties of Type I and Type II Interferon.

Authors:  Joseph Bekisz; Samuel Baron; Corey Balinsky; Angel Morrow; Kathryn C Zoon
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-30

10.  Stat1 activation attenuates IL-6 induced Stat3 activity but does not alter apoptosis sensitivity in multiple myeloma.

Authors:  Lina Y Dimberg; Anna Dimberg; Karolina Ivarsson; Mårten Fryknäs; Linda Rickardson; Gerard Tobin; Simon Ekman; Rolf Larsson; Urban Gullberg; Kenneth Nilsson; Fredrik Öberg; Helena Jernberg Wiklund
Journal:  BMC Cancer       Date:  2012-07-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.